Table 2.
Drug Doses and Response.
| Characteristics | N = 102 | |
|---|---|---|
| Imatinib treatment dose | ||
| 400 mg | No of patients (%) | 94 (92.1%) |
| 300 mg | No of patients (%) | 7 (6.8%) |
| 200 mg | No of patients (%) | 1 (0.98%) |
| BCR/ABL at sampling time | ||
| Unfavorable Response | Mean (SD) | 0.73 (1.37) |
| PD | Mean (SD) | 1.45 (0.05) |
| NR | Mean (SD) | 0.70 (1.38) |
| Favorable response | Mean (SD) | 0.007 (0.01) |
| CMR | Mean (SD) | 0 (0) |
| MMR | Mean (SD) | 0.002 (0.002) |
| CCyR | Mean (SD) | 0.04 (0.03) |
| Response after 1 year of follow-up | ||
| Unfavorable Response | No of patients (%) | 37 (36.6%) |
| PD | No of patients (%) | 3 (8%) |
| NR | No of patients (%) | 34 (92%) |
| Favorable response | No of patients (%) | 64 (63.4%) |
| CMR | No of patients (%) | 21 (33%) |
| MMR | No of patients (%) | 34 (53%) |
| CCyR | No of patients (%) | 9 (14%) |
| Response after 2 years of follow-up | ||
| Unfavorable response | No of patients (%) | 37 (36.6%) |
| PD | No of patients (%) | 3 (8%) |
| NR | No of patients (%) | 34 (92%) |
| Favorable response | No of patients (%) | 64 (63.4%) |
| CMR | No of patients (%) | 21 (33%) |
| MMR | No of patients (%) | 32 (50%) |
| CCyR | No of patients (%) | 11 (17%) |
SD, Standard Deviation; FR, Favorable Response; UF, Unfavorable Response; PD, Progressive Disease; NR, No Response; CMR, Complete Molecular Response; MMR, Major Molecular Response; CCyR, Complete Cytogenetic Response.